Evidence map›Paper›PMID 38539872›Full record

ArticleAntioxidants (Basel, Switzerland)2024

Advanced Oxidation Protein Products Are Strongly Associated with the Serum Levels and Lipid Contents of Lipoprotein Subclasses in Healthy Volunteers and Patients with Metabolic Syndrome.

Iva Klobučar, Lidija Hofmann, Hansjörg Habisch, Margarete Lechleitner, Lucija Klobučar, Matias Trbušić, Gudrun Pregartner, Andrea Berghold, Tobias Madl, Saša Frank and 1 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Low-Dose, Long-TermInternational journal of molecular sciences · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Evaluation ofMetabolites · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Iva KlobučarDepartment of Cardiology, Sisters of Charity University Hospital Centre, 10000 Zagreb, Croatia.ORCID 0000-0002-0640-7149
Lidija HofmannInstitute of Biomedical Science, Department of Health Studies, FH JOANNEUM University of Applied Sciences, 8020 Graz, Austria.
Hansjörg HabischOtto Loewi Research Center, Medicinal Chemistry, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0001-5537-506X
Margarete LechleitnerGottfried Schatz Research Center, Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.
Lucija KlobučarDepartment of Medicine, University Hospital Centre Osijek, 31000 Osijek, Croatia.
Matias TrbušićDepartment of Cardiology, Sisters of Charity University Hospital Centre, 10000 Zagreb, Croatia.
Gudrun PregartnerInstitute for Medical Informatics, Statistics und Documentation, Medical University of Graz, 8036 Graz, Austria.
Andrea BergholdInstitute for Medical Informatics, Statistics und Documentation, Medical University of Graz, 8036 Graz, Austria.
Tobias MadlOtto Loewi Research Center, Medicinal Chemistry, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0002-9725-5231
Saša FrankGottfried Schatz Research Center, Molecular Biology and Biochemistry, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0003-4826-7698
Vesna DegoricijaSchool of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Medical University of Graz · ATUniversity of Zagreb · HRFH JOANNEUM University of Applied Sciences · ATSisters of Charity Hospital · HRUniversity of Osijek · HR

Funding

Austrian Research Promotion Agency 864690 and 870454Austrian Science Fund FWF I 3792FWF Austrian Science Fund 10.55776/P28854, 10.5576/I3792, 10.55776/DOC-130, and 10.55776/W1226
6 · The paper itself

Abstract

The association between advanced oxidation protein products (AOPPs) and lipoprotein subclasses remains unexplored. Therefore, we performed comprehensive lipoprotein profiling of serum using NMR spectroscopy and examined the associations of lipoprotein subclasses with the serum levels of AOPPs in healthy volunteers (HVs) and patients with metabolic syndrome (MS). The serum levels of AOPPs were significantly positively correlated with the serum levels of very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL); however, they were significantly negatively correlated with high-density lipoprotein (HDL). These lipoproteins (and their subclasses) differed markedly regarding the direction of correlations between their lipid contents and AOPPs. The strength of the correlations and the relative contributions of the subclasses to the correlations were different in the HVs and patients with MS. As revealed by orthogonal partial least squares discriminant analyses, the serum levels of IDL were strong determinants of AOPPs in the HVs, whereas the serum levels of VLDL and the lipid content of LDL were strong determinants in both groups. We conclude that IDL, VLDL, and LDL facilitate, whereas HDL diminishes the bioavailability of serum AOPPs. The presence of MS and the lipid contents of the subclasses affect the relationship between lipoproteins and AOPPs.

Indexed as

advanced oxidation protein productslipoprotein profilingmetabolic syndromeNMR spectroscopy

Identifiers

PMID38539872
PMCPMC10968302
OpenAlexW4392709269

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.